US 11,702,545 B2
Nanoprobe-metal chelator complexes
Hak Soo Choi, Needham, MA (US); Jonghan Kim, Cambridge, MA (US); and Georges El Fakhri, Brookline, MA (US)
Assigned to The General Hospital Corporation, Boston, MA (US); and Northeastern University, Boston, MA (US)
Filed by The General Hospital Corporation, Boston, MA (US); and Northeastern University, Boston, MA (US)
Filed on Apr. 29, 2022, as Appl. No. 17/733,766.
Application 17/733,766 is a continuation of application No. 17/129,380, filed on Dec. 21, 2020, granted, now 11,339,294.
Application 17/129,380 is a continuation of application No. 16/484,722, granted, now 10,907,046, issued on Feb. 2, 2021, previously published as PCT/US2017/039888, filed on Jun. 29, 2017.
Claims priority of provisional application 62/456,210, filed on Feb. 8, 2017.
Prior Publication US 2022/0363905 A1, Nov. 17, 2022
Int. Cl. C09B 23/01 (2006.01); C09B 69/10 (2006.01)
CPC C09B 23/0066 (2013.01) [C09B 23/0025 (2013.01); C09B 23/0033 (2013.01); C09B 23/0041 (2013.01); C09B 69/105 (2013.01)] 21 Claims
 
1. A compound of Formula I:
A-B   I
or a pharmaceutically acceptable salt thereof, wherein:
A is selected from A-3, A-4, A-5, and A-6:

OG Complex Work Unit Chemistry
wherein:
custom character indicates the bond between A and B;
X is selected from the group consisting of a bond, C, CH2, NH, —NH—C1-6 alkylene-, O and S;
each RA is an independently selected anionic group selected from oxide, carbonate, carboxylate, phosphate, sulfide, sulfinate, and sulfonate;
each RC is an independently selected cationic group selected from ammonium, C1-6 alkylammonium, di(C1-6 alkyl)ammonium, and tri(C1-6 alkyl)ammonium; and
L1, L2, and L3 are each an independently selected C1-6 alkylene group;
B is a biocompatible polymer substituted by one or more C groups and one or more -D-E groups;
each C is independently selected from the group consisting of H and an anionic group;
each D is an independently selected linking group; and
each E is an independently selected metal chelating group.